Royce & Associates LP Raises Position in Simulations Plus, Inc. (NASDAQ:SLP)

Royce & Associates LP lifted its stake in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 56.6% during the fourth quarter, Holdings Channel reports. The fund owned 371,797 shares of the technology company’s stock after acquiring an additional 134,381 shares during the period. Royce & Associates LP’s holdings in Simulations Plus were worth $10,369,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SLP. Conestoga Capital Advisors LLC grew its holdings in Simulations Plus by 15.0% during the 4th quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company’s stock worth $62,090,000 after acquiring an additional 290,414 shares in the last quarter. State Street Corp raised its holdings in shares of Simulations Plus by 4.7% in the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company’s stock valued at $20,503,000 after purchasing an additional 28,953 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Simulations Plus by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock worth $14,367,000 after purchasing an additional 18,924 shares during the last quarter. Tributary Capital Management LLC increased its holdings in Simulations Plus by 21.7% in the fourth quarter. Tributary Capital Management LLC now owns 396,093 shares of the technology company’s stock valued at $11,047,000 after buying an additional 70,526 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Simulations Plus by 4.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 143,253 shares of the technology company’s stock valued at $3,995,000 after buying an additional 6,418 shares during the last quarter. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

Simulations Plus Stock Performance

Simulations Plus stock opened at $26.23 on Tuesday. The stock has a 50-day simple moving average of $31.57 and a 200-day simple moving average of $31.14. The company has a market capitalization of $527.01 million, a P/E ratio of 65.58 and a beta of 0.89. Simulations Plus, Inc. has a fifty-two week low of $24.00 and a fifty-two week high of $51.22.

Insider Buying and Selling at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total value of $678,200.00. Following the transaction, the director now directly owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 19.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. KeyCorp upped their price objective on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $49.40.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.